Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease (OMEGA-CD)
Modulation of Blood and Small Intestinal Inflammatory Processes and Fecal Microbiota in Celiac Disease Associated With the Intake of n-3 Polyunsaturated Fatty Acids
The goal of this clinical trial is to learn if omega-3 fatty acid supplements (n-3 PUFAs) can help reduce inflammation and promote intestinal healing in adults newly diagnosed with celiac disease (CD).
Celiac disease is a chronic autoimmune disorder where eating gluten-a protein found in wheat-triggers an immune response that damages the lining of the small intestine. This damage causes inflammation and symptoms such as stomach pain, diarrhea, and nutrient absorption problems. The only current treatment is a strict gluten-free diet (GFD), which can help most people recover, but some continue to have inflammation and symptoms.
This study will test whether supplementing with 2.4 grams of n-3 PUFAs daily for three months, alongside starting a gluten-free diet, reduces inflammation in the blood and intestine more effectively than the gluten-free diet alone.
Participants will:
Be adults recently diagnosed with celiac disease who have not yet started a gluten-free diet
Be randomly assigned to one of two groups:
One group will receive omega-3 supplements containing 2,400 mg of n-3 PUFAs daily (2,000 mg DHA and 400 mg EPA) The other group will receive a placebo (a pill with no active ingredients that looks like the supplement) Take the assigned supplement every day for 3 months while following a supervised gluten-free diet Visit the clinic regularly for checkups, blood tests, and monitoring of symptoms and diet adherence Provide blood and stool samples before and after the intervention to measure inflammation and changes in gut bacteria A subgroup of participants will undergo small intestinal biopsies to assess local inflammation and healing
The study aims to answer these main questions:
Does omega-3 supplementation change the fatty acid composition in blood cells? Does it reduce markers of inflammation in the blood and small intestine? Does it improve the diversity and health of gut bacteria in the intestine? Does it help the small intestine heal faster compared to diet alone?
Researchers will measure inflammation by analyzing immune signaling pathways, oxidative stress markers, and antioxidant activity in blood cells. They will also study the composition of the gut microbiota and its metabolites. These detailed measurements will help understand how omega-3 fatty acids may influence the immune response and gut health in celiac disease.
This is a randomized, double-blind, placebo-controlled crossover study. This means participants and researchers will not know who receives the supplement or placebo during the study period, reducing bias and improving the reliability of the results.
This study is important because it could offer a simple, additional treatment to improve recovery in celiac disease beyond the gluten-free diet. If omega-3 supplements are shown to reduce inflammation and support healing, they could become a valuable part of managing this chronic condition.
Participation is voluntary, and participants can leave the study at any time without affecting their medical care. All participants will be closely monitored to ensure safety throughout the study.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Karla A Bascuñán, PhD
- 電話番号:+56 2 9773232
- メール:kbascunan@uchile.cl
研究場所
-
-
Metropolitan Region
-
Santiago、Metropolitan Region、チリ、8380000
- 募集
- University of Chile Clinical Hospital
-
コンタクト:
- Paulina Toledo (Clinical Research Coordinator)+569
- 電話番号:987299944
- メール:ptoledo@hcuchi.cl
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult patients aged 18 to 65 years, Newly diagnosed with celiac disease confirmed by serology and intestinal biopsy, Not yet started gluten-free diet (GFD), Willingness to adhere to a supervised gluten-free diet during the study, Able to provide informed consent
Exclusion Criteria:
- Previous or current adherence to a gluten-free diet, Use of n-3 PUFA supplements or other dietary supplements influencing inflammation within the last 3 months, Presence of other autoimmune, inflammatory, or gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis), Pregnancy or breastfeeding, Severe chronic illnesses that may interfere with the study or outcomes (e.g., uncontrolled diabetes, cancer), Allergy or intolerance to fish oil or components of the supplement, Use of immunosuppressive or anti-inflammatory medication within the last 3 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Omega-3 PUFA Supplement
Participants in this group will receive daily oral supplementation with 2,400 mg of omega-3 polyunsaturated fatty acids (2,000 mg DHA and 400 mg EPA) for 3 months.
All participants will start a supervised gluten-free diet at the same time.
Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
|
n-3 PUFAs supplementation consisting of 2,400 mg per day (2,000 mg docosahexaenoic acid [DHA] and 400 mg eicosapentaenoic acid [EPA]), administered orally for 3 months in newly diagnosed adult celiac disease patients.
The supplementation is given alongside the initiation of a gluten-free diet (GFD).
The aim is to assess whether supplementation modulates the inflammatory response and supports intestinal recovery.
This is part of a randomized, double-blind, placebo-controlled, crossover trial comparing supplementation versus placebo.
他の名前:
|
|
プラセボコンパレーター:Placebo
Participants in this group will receive a daily oral placebo supplement, identical in appearance and taste to the omega-3 supplement, for 3 months.
All participants will begin a supervised gluten-free diet at the same time.
Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
|
Placebo capsules identical in appearance and taste to the active n-3 polyunsaturated fatty acid (PUFA) supplement, administered orally once daily for 3 months in newly diagnosed adult celiac disease patients.
Participants will simultaneously begin a supervised gluten-free diet.
This intervention serves as a control to evaluate the effect of the active supplement on modulating the inflammatory response and intestinal recovery.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Modulation of systemic inflammatory response via cytokine levels and NF-κB signaling in peripheral blood mononuclear cells
時間枠:From baseline (T0) to 3 months (T3) of supplementation
|
Levels of proinflammatory cytokines and NF-κB signaling in peripheral blood mononuclear cells will be measured to assess the reduction of systemic inflammation in newly diagnosed adult celiac patients receiving n-3 PUFA supplementation versus placebo.
|
From baseline (T0) to 3 months (T3) of supplementation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in fatty acid composition of erythrocyte and peripheral blood mononuclear cell membranes
時間枠:From baseline (T0) to 3 months (T3) of supplementation
|
The fatty acid profiles of erythrocyte and peripheral blood mononuclear cell membranes will be analyzed at baseline and after 3 months to assess the impact of n-3 PUFA supplementation on membrane lipid composition in adult celiac disease patients.
|
From baseline (T0) to 3 months (T3) of supplementation
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluation of intestinal inflammation and microbiota composition in newly diagnosed celiac disease patients following n-3 PUFA supplementation
時間枠:From baseline (T0) to 3 months post-intervention (T3)
|
Assessment of local intestinal inflammation and gut microbiota changes in newly diagnosed adult celiac disease patients receiving 2.4 g/day of n-3 polyunsaturated fatty acids alongside a supervised gluten-free diet. Intestinal biopsies and fecal samples will be collected at baseline (T0) and after 3 months (T3) to measure inflammatory markers (e.g., NFκB, pro-inflammatory cytokines, I-FABP) and characterize fecal microbiota diversity and short-chain fatty acid profiles. This will determine the impact of n-3 PUFA supplementation on mucosal inflammation and the intestinal microenvironment. Time Frame: |
From baseline (T0) to 3 months post-intervention (T3)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 11240685
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。